An experimental cancer vaccine developed by Moderna and Merck has shown promising results in reducing the risk of melanoma recurrence. The vaccine, named intismeran, is personalized for each patient based on their tumor characteristics. According to the study results released by the companies on Thursday, the vaccine cut the risk of melanoma returning by 42% when combined with standard treatment after surgery.
The findings are based on the most advanced study yet of this approach, measuring recurrence risk over two years post-surgery. The vaccine utilizes mRNA technology, the same innovation behind COVID-19 vaccines, which won a Nobel Prize. Dr. Hussein Tawbi of MD Anderson Cancer Centre in Houston, a researcher involved in the international study, described the results as a significant breakthrough.
Researchers are also exploring similar personalized vaccines for other cancers, including lung, kidney, and pancreas. The study highlights the potential of mRNA technology in cancer treatment, offering hope for more effective and tailored therapies in the future.